glp-1 pediatric obesity management algorithm. BMI, body mass index; GLP1, Dietary recommendations for pediatric and
Description
GLP-1

Retatrutide (research phase) Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors

G., Balthasar, N., Heisler, L

The STEP 1 trial, which tested semaglutide 2.4mg in adults with obesity, found that approximately 39% of weight lost was lean mass after 68 weeks

Starting doses vary by product: semaglutide typically starts at 0.25 mg weekly, dulaglutide at 0.75 mg weekly, tirzepatide at 2.5 mg weekly, while liraglutide begins at 0.6 mg daily
